206 related articles for article (PubMed ID: 22422487)
1. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis.
Sakai R; Komano Y; Tanaka M; Nanki T; Koike R; Nagasawa H; Amano K; Nakajima A; Atsumi T; Koike T; Ihata A; Ishigatsubo Y; Saito K; Tanaka Y; Ito S; Sumida T; Tohma S; Tamura N; Fujii T; Sugihara T; Kawakami A; Hagino N; Ueki Y; Hashiramoto A; Nagasaka K; Miyasaka N; Harigai M;
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1125-34. PubMed ID: 22422487
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
5. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
6. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
7. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
9. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
10. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N
Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
[TBL] [Abstract][Full Text] [Related]
12. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
[TBL] [Abstract][Full Text] [Related]
14. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.
Gomez-Reino JJ; Carmona L;
Arthritis Res Ther; 2006; 8(1):R29. PubMed ID: 16507128
[TBL] [Abstract][Full Text] [Related]
15. Infections in patients with rheumatoid arthritis treated with biologic agents.
Listing J; Strangfeld A; Kary S; Rau R; von Hinueber U; Stoyanova-Scholz M; Gromnica-Ihle E; Antoni C; Herzer P; Kekow J; Schneider M; Zink A
Arthritis Rheum; 2005 Nov; 52(11):3403-12. PubMed ID: 16255017
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven RF; Klareskog L
Ann Rheum Dis; 2007 Oct; 66(10):1339-44. PubMed ID: 17261532
[TBL] [Abstract][Full Text] [Related]
17. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
[TBL] [Abstract][Full Text] [Related]
18. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
[TBL] [Abstract][Full Text] [Related]
19. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
20. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
Wolfe F; Michaud K
Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]